PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 20, 2023Cureus8 citationsOpen Access

Thyrotoxicosis-Induced Cardiomyopathy With Systolic Dysfunction

YKYusuf KhalilMDMichael D DubeLWLarry Woods

Key Result

Methimazole, metoprolol, and sacubitril/valsartan therapy successfully reversed thyrotoxicosis-induced dilated cardiomyopathy, improving the patient's ejection fraction from 36% to 56%.

Study Design

Type

Case Report (n=1)

Multicenter

No

Structured PICO

P
Population
1 39-year-old African American male with a history of tobacco, cannabinoid, and fentanyl use, presenting with thyrotoxicosis-induced acute heart failure (LVEF 36%) secondary to Grave's disease.
I
Intervention
Methimazole 20 mg oral twice daily, metoprolol 50 mg oral daily, and sacubitril/valsartan 49/51 mg oral twice daily.
O
Outcome
Reversal of cardiac dysfunction (ejection fraction) and return to baseline functional status at 6 weeks.surrogate

Prompt intensive treatment of thyrotoxicosis-induced cardiomyopathy with anti-thyroid and heart failure medications can rapidly reverse severe left ventricular systolic dysfunction.

Limitations

  • Reversibility of hyperthyroidism-induced ventricular dysfunction may vary among patients
  • Need for more research to better understand the underlying mechanisms and long-term outcomes of hyperthyroidism-induced cardiomyopathy

Abstract

Thyrotoxicosis-induced dilated cardiomyopathy is a rare but potentially life-threatening complication of thyrotoxicosis, with an incidence of <1%. This condition is characterized by a dilatation of the ventricular chamber and a decrease in cardiac contractility. Untreated, it can lead to irreversible changes in cardiac structure and function, including dilated ventricular chamber, a decrease in ejection fraction (EF), and an increased risk of atrial fibrillation. We present a case of a 39-year-old patient with a diagnosis of thyrotoxicosis-induced acute heart failure. A two-dimensional (2D) echocardiogram disclosed an ejection fraction of 36%, with diffuse mild dilation of the atria and ventricles with trace mitral and tricuspid regurgitation. The anti-thyroid-stimulating hormone (TSH) receptor was positive, and Grave's disease was diagnosed. The patient eventually returned to baseline functional status and could return to basic activities of daily living without limitations. The patient was encouraged to follow up with outpatient cardiology. Early diagnosis of cardiac involvement in patients with thyrotoxicosis is critical. Promptly delivered intensive treatment with the rapid achievement of euthyroid state can potentially reverse cardiac dysfunction and improve patient outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Khalil et al. (2023) conducted a case report in Thyrotoxicosis-induced dilated cardiomyopathy (n=1). Methimazole, metoprolol, and sacubitril/valsartan was evaluated on Left ventricular ejection fraction. Methimazole, metoprolol, and sacubitril/valsartan therapy successfully reversed thyrotoxicosis-induced dilated cardiomyopathy, improving the patient's ejection fraction from 36% to 56%.

synapsesocial.com/papers/6a0961d1a9b58856443410behttps://doi.org/10.7759/cureus.33988
Ask AI
Helpful
Bookmark
Share
View Full Paper